Inhibiting cancer cell hallmark features through nuclear export inhibition

Qingxiang Sun, Xueqin Chen, Qiao Zhou, Ezra Burstein, Shengyong Yang, Da Jia

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Treating cancer through inhibition of nuclear export is one of the best examples of basic research translation into clinical application. Nuclear export factor chromosomal region maintenance 1 (CRM1; Xpo1 and exportin-1) controls cellular localization and function of numerous proteins that are critical for the development of many cancer hallmarks. The diverse actions of CRM1 are likely to explain the broad ranging anti-cancer potency of CRM1 inhibitors observed in pre-clinical studies and/or clinical trials (phase I–III) on both advanced-stage solid and hematological tumors. In this review, we compare and contrast the mechanisms of action of different CRM1 inhibitors, and discuss the potential benefit of unexplored non-covalent CRM1 inhibitors. This emerging field has uncovered that nuclear export inhibition is well poised as an attractive target towards low-toxicity broad-spectrum potent anti-cancer therapy.

Original languageEnglish (US)
Article number16010
JournalSignal Transduction and Targeted Therapy
Volume1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Cell Nucleus Active Transport
Neoplasms
Maintenance
Clinical Trials
Research
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Inhibiting cancer cell hallmark features through nuclear export inhibition. / Sun, Qingxiang; Chen, Xueqin; Zhou, Qiao; Burstein, Ezra; Yang, Shengyong; Jia, Da.

In: Signal Transduction and Targeted Therapy, Vol. 1, 16010, 01.01.2016.

Research output: Contribution to journalReview article

Sun, Qingxiang ; Chen, Xueqin ; Zhou, Qiao ; Burstein, Ezra ; Yang, Shengyong ; Jia, Da. / Inhibiting cancer cell hallmark features through nuclear export inhibition. In: Signal Transduction and Targeted Therapy. 2016 ; Vol. 1.
@article{18df93566cbb429fbd138afbc459f4c7,
title = "Inhibiting cancer cell hallmark features through nuclear export inhibition",
abstract = "Treating cancer through inhibition of nuclear export is one of the best examples of basic research translation into clinical application. Nuclear export factor chromosomal region maintenance 1 (CRM1; Xpo1 and exportin-1) controls cellular localization and function of numerous proteins that are critical for the development of many cancer hallmarks. The diverse actions of CRM1 are likely to explain the broad ranging anti-cancer potency of CRM1 inhibitors observed in pre-clinical studies and/or clinical trials (phase I–III) on both advanced-stage solid and hematological tumors. In this review, we compare and contrast the mechanisms of action of different CRM1 inhibitors, and discuss the potential benefit of unexplored non-covalent CRM1 inhibitors. This emerging field has uncovered that nuclear export inhibition is well poised as an attractive target towards low-toxicity broad-spectrum potent anti-cancer therapy.",
author = "Qingxiang Sun and Xueqin Chen and Qiao Zhou and Ezra Burstein and Shengyong Yang and Da Jia",
year = "2016",
month = "1",
day = "1",
doi = "10.1038/sigtrans.2016.10",
language = "English (US)",
volume = "1",
journal = "Signal Transduction and Targeted Therapy",
issn = "2095-9907",
publisher = "Springer Nature",

}

TY - JOUR

T1 - Inhibiting cancer cell hallmark features through nuclear export inhibition

AU - Sun, Qingxiang

AU - Chen, Xueqin

AU - Zhou, Qiao

AU - Burstein, Ezra

AU - Yang, Shengyong

AU - Jia, Da

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Treating cancer through inhibition of nuclear export is one of the best examples of basic research translation into clinical application. Nuclear export factor chromosomal region maintenance 1 (CRM1; Xpo1 and exportin-1) controls cellular localization and function of numerous proteins that are critical for the development of many cancer hallmarks. The diverse actions of CRM1 are likely to explain the broad ranging anti-cancer potency of CRM1 inhibitors observed in pre-clinical studies and/or clinical trials (phase I–III) on both advanced-stage solid and hematological tumors. In this review, we compare and contrast the mechanisms of action of different CRM1 inhibitors, and discuss the potential benefit of unexplored non-covalent CRM1 inhibitors. This emerging field has uncovered that nuclear export inhibition is well poised as an attractive target towards low-toxicity broad-spectrum potent anti-cancer therapy.

AB - Treating cancer through inhibition of nuclear export is one of the best examples of basic research translation into clinical application. Nuclear export factor chromosomal region maintenance 1 (CRM1; Xpo1 and exportin-1) controls cellular localization and function of numerous proteins that are critical for the development of many cancer hallmarks. The diverse actions of CRM1 are likely to explain the broad ranging anti-cancer potency of CRM1 inhibitors observed in pre-clinical studies and/or clinical trials (phase I–III) on both advanced-stage solid and hematological tumors. In this review, we compare and contrast the mechanisms of action of different CRM1 inhibitors, and discuss the potential benefit of unexplored non-covalent CRM1 inhibitors. This emerging field has uncovered that nuclear export inhibition is well poised as an attractive target towards low-toxicity broad-spectrum potent anti-cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=85008688904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008688904&partnerID=8YFLogxK

U2 - 10.1038/sigtrans.2016.10

DO - 10.1038/sigtrans.2016.10

M3 - Review article

VL - 1

JO - Signal Transduction and Targeted Therapy

JF - Signal Transduction and Targeted Therapy

SN - 2095-9907

M1 - 16010

ER -